LRRK2 and Parkinson disease: The human LRRK2 G2019S variant, as well as the suppression of the LRRK2 wild-type in transgenic mouse models of PD, did not aggravate the behavioral problems or neurochemical phenotype derived from human A53T α-syn expression [203].